Convalescent plasma therapy in patients withCOVID-19

Basit Öğe Kaydı
dc.authoridYigenoglu, Tugce/0000-0001-9962-8882
dc.authoridBasturk, Abdulkadir/0000-0003-1864-0316
dc.authoridHacıbekiroğlu, Tuba/0000-0003-1814-5972
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authorwosidUlas, Turgay TU/A-6050-2018
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorHacibekiroglu, Tuba
dc.contributor.authorBerber, Ilhami
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorBasturk, Abdulkadir
dc.contributor.authorNamdaroglu, Sinem
dc.contributor.authorKorkmaz, Serdal
dc.date.accessioned2024-08-04T20:48:44Z
dc.date.available2024-08-04T20:48:44Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThere are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID-19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID-19. CP may be an adjunctive treatment option to the anti-viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200-600 mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID-19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.en_US
dc.identifier.doi10.1002/jca.21806
dc.identifier.endpage373en_US
dc.identifier.issn0733-2459
dc.identifier.issn1098-1101
dc.identifier.issue4en_US
dc.identifier.pmid32643200en_US
dc.identifier.scopus2-s2.0-85087740794en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage367en_US
dc.identifier.urihttps://doi.org/10.1002/jca.21806
dc.identifier.urihttps://hdl.handle.net/11616/99409
dc.identifier.volume35en_US
dc.identifier.wosWOS:000547463700001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Clinical Apheresisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectconvalescent plasmaen_US
dc.subjectCOVID-19en_US
dc.subjectSARS CoV-2en_US
dc.titleConvalescent plasma therapy in patients withCOVID-19en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu